🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Biocity Biopharmaceutics clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China and USA registers with Biocity Biopharmaceutics as lead sponsor. Synced 26 Sep 2026
5Current trials
4Recruiting now
2Drugs in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Biocity Biopharmaceutics is the lead sponsor of 5 current clinical trials in our China and USA registers. 4 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are BC3195 and Pembrolizumab KEYTRUDA. The most-studied condition is Advanced Cancer.

ClinicalTrials.gov trials by status

  • Recruiting480%
  • Active, closed120%

Trials by phase

  • Phase 1240%
  • Phase 3120%
  • Phase 2120%
  • Phase 1/2120%
01

Clinical trials sponsored by Biocity Biopharmaceutics

5 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
NCT06819826 · ClinicalTrials.gov ↗ · IgA Nephropathy (IgAN)
Phase 3 Recruiting 2025-02 China
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer
NCT06548672 · ClinicalTrials.gov ↗ · Advanced Cancer, Metastatic Solid Tumor
Drug: BC3195
Phase 1 Recruiting 2024-06 USA
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies
NCT07368478 · ClinicalTrials.gov ↗ · Advanced Solid Malignancies
Phase 1 Recruiting 2025-11 China
BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT07469774 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting 2026-03 China
A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease
NCT05687890 · ClinicalTrials.gov ↗ · Diabetic Kidney Disease, IgA Nephropathy
Phase 2 Active, closed 2023-05 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Biocity Biopharmaceutics trials

2 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Biocity Biopharmaceutics trials

7 conditions
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China43
Clinical trials in USA11

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Advanced Cancer

SponsorTrials
Chia Tai Tianqing Pharmaceutical Group3
Mirati Therapeutics2
Arcus Biosciences2
Transcenta Therapeutics (Hangzhou)2
Agenus1
MacroGenics1
Solve Therapeutics1
HC Biopharma1

Sponsors with the most current trials registered for this condition.

06

Questions about Biocity Biopharmaceutics trials

How many clinical trials does Biocity Biopharmaceutics sponsor?

Biocity Biopharmaceutics is the lead sponsor of 5 current trials on ClinicalTrials.gov in our China and USA registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Biocity Biopharmaceutics trials recruiting?

Yes. 4 of its 5 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Biocity Biopharmaceutics testing?

Its current trials name 2 drugs and biologicals as interventions. The most frequent are BC3195 (2) and Pembrolizumab KEYTRUDA (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.